Hans-Guido Wendel: Publications

The Hans-Guido Wendel Lab
Research Overview
Featured News
Publications
Open Positions

Hans-Guido Wendel: Publications

Share
Share
  1. The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase. Sanghvi VR, Leibold J, Mina M, Mohan P, Berishaj M, Li Z, Miele MM, Lailler N, Zhao C, de Stanchina E, Viale A, Akkari L, Lowe SW, Ciriello G, Hendrickson RC, Wendel HG. Cell. 2019 Aug 8;178(4):807-819.e21. doi: 10.1016/j.cell.2019.07.031.PMID: 31398338
  2. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan WC, Malek SN, Ennishi D, Brentjens RJ, Gascoyne RD, Cogné M, Tarte K, Wendel HG. Cell. 2016 Oct 6;167(2):405-418.e13. doi: 10.1016/j.cell.2016.08.032. Epub 2016 Sep 29.PMID: 27693350 
  3. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA Jr, Pelletier J, Rätsch G, Wendel HG. Nature. 2014 Sep 4;513(7516):65-70. doi: 10.1038/nature13485. Epub 2014 Jul 27.PMID: 25079319 
  4. The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. Parsa S, Ortega-Molina A, Jiang M, De Stanchina E, Ciriello G, Green M, Birsoy K, Melnick AM, Wendel HG. Nature Cancer 2020 in press
  5. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol. Müller C, Obermann W, Schulte FW, Lange-Grünweller K, Oestereich L, Elgner F, Glitscher M, Hildt E, Singh K, Wendel HG, Hartmann RK, Ziebuhr J, Grünweller A. Antiviral Res. 2020 Mar;175:104706. doi: 10.1016/j.antiviral.2020.104706. Epub 2020 Jan 10.PMID: 31931103 
  6. The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase. Sanghvi VR, Leibold J, Mina M, Mohan P, Berishaj M, Li Z, Miele MM, Lailler N, Zhao C, de Stanchina E, Viale A, Akkari L, Lowe SW, Ciriello G, Hendrickson RC, Wendel HG. Cell. 2019 Aug 8;178(4):807-819.e21. doi: 10.1016/j.cell.2019.07.031.PMID: 31398338
  7. Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. Wang S, Mondal S, Zhao C, Berishaj M, Ghanakota P, Batlevi CL, Dogan A, Seshan VE, Abel R, Green MR, Younes A, Wendel HG. JCI Insight. 2019 Jun 20;4(12):e127566. doi: 10.1172/jci.insight.127566. eCollection 2019 Jun 20.PMID: 31217352 
  8. c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma. Singh K, Lin J, Zhong Y, Burčul A, Mohan P, Jiang M, Sun L, Yong-Gonzalez V, Viale A, Cross JR, Hendrickson RC, Rätsch G, Ouyang Z, Wendel HG. J Exp Med. 2019 Jul 1;216(7):1509-1524. doi: 10.1084/jem.20181726. Epub 2019 May 29.PMID: 31142587
  9. Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Oricchio E, Katanayeva N, Donaldson MC, Sungalee S, Pasion JP, Béguelin W, Battistello E, Sanghvi VR, Jiang M, Jiang Y, Teater M, Parmigiani A, Budanov AV, Chan FC, Shah SP, Kridel R, Melnick AM, Ciriello G, Wendel HG. Sci Transl Med. 2017 Jun 28;9(396):eaak9969. doi: 10.1126/scitranslmed.aak9969.PMID: 28659443 
  10. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu CS, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel HG*, Melnick AM*. Cancer Discov. 2017 Jan;7(1):38-53. doi: 10.1158/2159-8290.CD-16-0975. Epub 2016 Oct 12.PMID: 27733359 
  11. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan WC, Malek SN, Ennishi D, Brentjens RJ, Gascoyne RD, Cogné M, Tarte K, Wendel HG. Cell. 2016 Oct 6;167(2):405-418.e13. doi: 10.1016/j.cell.2016.08.032. Epub 2016 Sep 29.PMID: 27693350 
  12. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I, Lee JE, Chen HT, Ennishi D, Scott DW, Mottok A, Hother C, Liu S, Cao XJ, Tam W, Shaknovich R, Garcia BA, Gascoyne RD, Ge K, Shilatifard A, Elemento O, Nussenzweig A, Melnick AM, Wendel HG. Nat Med. 2015 Oct;21(10):1199-208. doi: 10.1038/nm.3943. Epub 2015 Sep 14.PMID: 26366710 
  13. Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia. Sanghvi VR, Mavrakis KJ, Van der Meulen J, Boice M, Wolfe AL, Carty M, Mohan P, Rondou P, Socci ND, Benoit Y, Taghon T, Van Vlierberghe P, Leslie CS, Speleman F, Wendel HG. Sci Signal. 2014 Nov 18;7(352):ra111. doi: 10.1126/scisignal.2005500.PMID: 25406379 
  14. A cell engineering strategy to enhance the safety of stem cell therapies. Oricchio E, Papapetrou EP, Lafaille F, Ganat YM, Kriks S, Ortega-Molina A, Mark WH, Teruya-Feldstein J, Huse JT, Reuter V, Sadelain M, Studer L, Wendel HG. Cell Rep. 2014 Sep 25;8(6):1677-1685. doi: 10.1016/j.celrep.2014.08.039. Epub 2014 Sep 18.PMID: 25242333 
  15. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA Jr, Pelletier J, Rätsch G, Wendel HG. Nature. 2014 Sep 4;513(7516):65-70. doi: 10.1038/nature13485. Epub 2014 Jul 27.PMID: 25079319 
  16. Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. Oricchio E, Ciriello G, Jiang M, Boice MH, Schatz JH, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J, Bouska A, McKeithan T, Sander C, Tam W, Seshan VE, Chan WC, Chaganti RS, Wendel HG.J Exp Med. 2014 Jun 30;211(7):1379-91. doi: 10.1084/jem.20132120. Epub 2014 Jun 9.PMID: 24913233 
  17. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick A, Himanen JP, Chaganti RS, Wendel HG. Cell 2011 Oct 28;147(3):554-64. doi: 10.1016/j.cell.2011.09.035.PMID: 22036564 
  18. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Rajasekhar VK, Pagano NC, Porco JA Jr, Teruya-Feldstein J, Rosen N, Zelenetz AD, Pelletier J, Wendel HG.J Exp Med. 2011 Aug 29;208(9):1799-807. doi: 10.1084/jem.20110846.
  19. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon T, Khan AA, Setty M, Rondou P, Vandenberghe P, Delabesse E, Benoit Y, Socci NB, Leslie CS, Van Vlierberghe P, Speleman F,Wendel HG. Nat Genet. 2011 Jun 5;43(7):673-8. doi: 10.1038/ng.858.PMID: 21642990 
  20. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, Zuber J, James T, Khan AA, Leslie CS, Parker JS, Paddison PJ, Tam W, Ferrando A, Wendel HG. Nat Cell Biol. 2010 Apr;12(4):372-9. doi: 10.1038/ncb2037. Epub 2010 Feb 28.PMID: 20190740 
  21. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Mavrakis KJ, Zhu H, Silva RL, Mills JR, Teruya-Feldstein J, Lowe SW, Tam W, Pelletier J, Wendel HG. Genes Dev. 2008 Aug 15;22(16):2178-88. doi: 10.1101/gad.1690808.PMID: 18708578 
  22. Dissecting eIF4E action in tumorigenesis. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, Lowe SW. Genes Dev. 2007 Dec 15;21(24):3232-7. doi: 10.1101/gad.1604407. Epub 2007 Nov 30.PMID: 18055695 
  23. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Nature. 2004 Mar 18;428(6980):332-7.
  24. Reviews
  25. Emerging epigenetic-modulating therapies in lymphoma. Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Nat Rev Clin Oncol. 2019 Aug;16(8):494-507. doi: 10.1038/s41571-019-0190-8.PMID: 30837715